All In Biotech

Drug Trial Radar · NCT05871905

[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Subjects

[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Adult Male Subjects

Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Jun 19, 2023

Primary completion

Nov 6, 2023

Study completion Jun 20, 2024

Sponsor

Lead sponsor
TYK Medicines, IncIndustry
Sponsor type
Industry
First posted
May 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

\[14 C\] Mass balance clinical trial of TY-9591 in healthy Chinese subjects

Conditions

  • Healthy Volunteers

Interventions

  • TY-9591Drug

    C14 TY-9591

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The total radioactivity in whole blood and plasma after a single oral administration of 14C TY-9591Time frame: After oral administration of 14C TY-9591, the radiometabolite profiles of plasma, urine and stool were obtained to identify the major metabolites

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Suzhou first people's hospital

    Suzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.